Probatebeta
Drug

Acoramidis

As of the edition of 20 October 2026, Acoramidis is a small molecule: marketed, first approved in 2024 (US); acts on TTR; US protection ends in 2038.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status
Marketed; latest approval 2025
Kind
Small molecule
Brand name
Attruby
First approved
22 November 2024 (US)
Approvals on record
5 in 4 regions
Holder of the most recent approval
Bayer; 4 holders in all
Registered trials
16, 2 stopped early
Disease areas
Nutrition and metabolism; Inherited and neonatal; Nervous system; Heart and blood vessels; Mental health

US protection

US protection ends in 2038.

The last listed US drug-substance patent ends in 2038. The application that gives this date is held by Bridgebio Pharma.

This is the US only, and it is not the date generics or biosimilars can enter.

The exact date and the listings behind it

In the product

4 listings count towards this date. The exact date and each listing are in the product.

See the exact date and the 4 listings behind itRequest access. Nothing is shown until you do.

Companies that need a new molecule because of this drug

3 companies on route B because of this drug.

Companies on route B for this drug

In the product

3 companies are on route B because of Acoramidis.

See the 3 companies on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.

Target

GeneProteinUniProt
TTRTransthyretinP02766

Registered trials

PhaseTrialsCompletedActiveStopped early
Phase not stated2020
Phase 13300
Phase 21010
Phase 37232
Phase 43030
All trials16

Who has held its approvals

CompanyRoleYears
AstraZenecaApplicant and Lead sponsor of trials2020 to now
Bridgebio PharmaOriginator2024 to now
BayerApplicant and Lead sponsor of trials2025 to now

Other drugs at TTR

All of TTR

Other marketed drugs held by Bayer

Bayer

Other drugs whose US protection ends in 2038